A Clinical Approach to Psychedelic Experiences
Research into psychedelic-assisted therapy has expanded significantly in recent years. Substances like psilocybin, MDMA, and LSD are being studied for their impact on depression, anxiety, PTSD, and overall well-being. Organizations like MAPS (Multidisciplinary Association for Psychedelic Studies) have been at the forefront of this research.
Many of the founders and executives I work with are exploring psychedelic experiences as a tool for deeper self-understanding. Not as recreation, but as an extension of the intentional, high-performance approach they bring to everything else in their lives. What is often missing is a clinical structure around those experiences. These are people who would never go into a business decision without preparation and a framework for evaluating outcomes. Psychedelic experiences deserve the same rigor.



